Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study


Por: del Alcazar, E, Ferran, M, Lopez-Ferrer, A, Notario, J, Vidal, D, Riera, J, Aparicio, G, Gallardo, F, Vilarrasa, E, Alsina, M, Puig, L, Ferrandiz, C, Carrascosa, JM

Publicada: 2 abr 2020
Resumen:
Background: Scant information from clinical practice is available on the effectiveness and safety of ustekinumab (UST) 90 mg in patients with psoriasis weighing 100 kg or less. Objectives: To assess the effectiveness and safety at weeks 16 and 24 of UST 90 mg in patients with psoriasis weighing <= 100 kg, and to study the impact on clinical outcomes of body mass index (BMI) and prior exposure to UST 45 mg. Methods: A retrospective, observational, and multicenter study of 74 adult patients who were treated with UST 90 mg at least 24 weeks. Results: Mean (standard deviation [SD]) score on psoriasis area and severity index (PASI) was 7.9 (4.8) at baseline, 3.3 (3.5) at week 16, and 2.2 (2.4) at week 24, when 69.7% of the patients had a PASI under 3. Overweight and obese patients achieved a mean PASI of 2.2 by week 24 (p= .995). In patients who had previously been treated with UST 45 mg (52/74) with insufficient response, mean (SD) absolute PASI score was 2.7 (2.6) at week 24. No serious adverse events were reported. Conclusions: In patients who weigh 100 kg or less but are overweight or obese and do not present an adequate response with UST 45 mg, increasing the dose to UST 90 mg could be an alternative option.

Filiaciones:
del Alcazar, E:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Dept Dermatol, Badalona, Spain

 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Dept Dermatol, Crta Canyet S-N, Badalona, Spain

Ferran, M:
 Univ Autonoma Barcelona, Hosp del Mar, Inst Mar Invest Med, Dept Dermatol,UAB, Barcelona, Spain

Lopez-Ferrer, A:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Dermatol, UAB, Barcelona, Spain

Notario, J:
 Univ Barcelona, Hosp Univ Bellvitge, Dept Dermatol, Lhospitalet De Llobregat, Spain

Vidal, D:
 Hosp St Joan Despi Moises Broggi, Dept Dermatol, St Joan Despi, Spain

Riera, J:
 Univ Barcelona, Hosp Clin, Dept Dermatol, Barcelona, Spain

Aparicio, G:
 Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Dermatol, UAB, Barcelona, Spain

Gallardo, F:
 Univ Autonoma Barcelona, Hosp del Mar, Inst Mar Invest Med, Dept Dermatol,UAB, Barcelona, Spain

Vilarrasa, E:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Dermatol, UAB, Barcelona, Spain

Alsina, M:
 Univ Barcelona, Hosp Clin, Dept Dermatol, Barcelona, Spain

Puig, L:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Dermatol, UAB, Barcelona, Spain

Ferrandiz, C:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Dept Dermatol, Badalona, Spain

Carrascosa, JM:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Dept Dermatol, Badalona, Spain
ISSN: 09546634
Editorial
TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND, Suecia
Tipo de documento: Article
Volumen: 31 Número: 3
Páginas: 222-226
WOS Id: 000518097600003
ID de PubMed: 30883242
imagen Green Accepted

MÉTRICAS